NASDAQ:CALA - Calithera Biosciences Stock Price, Price Target & More

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences (NASDAQ:CALA) announced its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.05. The biotechnology company earned $5.19 million during the quarter, compared to the consensus estimate of $7.28 million. Calithera Biosciences had a negative return on equity of 22.92% and a negative net margin of 131.51%. View Calithera Biosciences' Earnings History.

5 Wall Street analysts have issued 12-month price objectives for Calithera Biosciences' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Calithera Biosciences' share price to reach $17.6667 in the next year. View Analyst Ratings for Calithera Biosciences.

Some companies that are related to Calithera Biosciences include Amphastar Pharmaceuticals (AMPH), Abeona Therapeutics (ABEO), GlycoMimetics (GLYC), Vectura Group (VEGPF), ANI Pharmaceuticals Inc Common Stock (ANIP), Homology Medicines (FIXX), Dicerna Pharmaceuticals (DRNA), CymaBay Therapeutics (CBAY), Arcus Biosciences (RCUS), Dova Pharmaceuticals (DOVA), Aduro BioTech (ADRO), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), ChemoCentryx (CCXI) and Odonate Therapeutics (ODT).

News coverage about CALA stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Calithera Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.01%), Federated Investors Inc. PA (3.97%), American Century Companies Inc. (2.22%), Millennium Management LLC (1.99%), Franklin Resources Inc. (1.79%) and Dimensional Fund Advisors LP (1.32%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.

CALA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Franklin Resources Inc. and Barclays PLC. Company insiders that have sold Calithera Biosciences company stock in the last year include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Insider Buying and Selling for Calithera Biosciences.

CALA stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, BlackRock Inc., Dimensional Fund Advisors LP, American Century Companies Inc., GSA Capital Partners LLP, Candriam Luxembourg S.C.A., Alambic Investment Management L.P. and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. View Insider Buying and Selling for Calithera Biosciences.

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CALA stock can currently be purchased for approximately $5.25.

Calithera Biosciences has a market capitalization of $193.56 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]